Floatz logo

Autologous Nk Cells

Squamous Cell Lung Cancer

Envita Medical Center, Inc.Cell therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

47 Active assets in the Squamous Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Qilu Hospital of Shandong University
Phase 4BBB
Carboplatin
zhang yi
Phase 3BBB
Docetaxel
Shanghai JMT-Bio Inc.
Phase 3BBB
Cyclophosphamide
UNC Lineberger Comprehensive Cancer Center
Phase 3BB
ETOPOSIDE
Barbara Ann Karmanos Cancer Institute
Phase 3BB

View all 50 →

Same molecule, other indications

Autologous Nk Cells is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
57 / 100
View asset →
Persistent/Recurrent Minimal Residual Disease (MRD)Dormant
CC
Indicative ·
47 / 100
View asset →
hepatocellular carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →